Search This Blog

Monday, June 5, 2017

First Presentation of Efficacy Data from CheckMate -204 Evaluating the Combination of Opdivo (nivolumab) and Yervoy (ipilimumab) Demonstrates Anti-tumor Activity in Advanced Melanoma Patients with Brain Metastases | BMS Newsroom

Over half of patients (55%) experienced an intracranial objective response with 21% achieving a complete intracranial response



First Presentation of Efficacy Data from CheckMate -204 Evaluating the Combination of Opdivo (nivolumab) and Yervoy (ipilimumab) Demonstrates Anti-tumor Activity in Advanced Melanoma Patients with Brain Metastases | BMS Newsroom

No comments:

Post a Comment